Endocare signs a distribution agreement with R-Action Distribution Sarl

Endocare Inc. announced this week it has signed an exclusive agreement with R-Action Distribution Sarl, which is a subsidiary of R-Action SAS, that will allow the distribution of its Endocare Cryoablation technology in France and Switzerland.

The first location the technology will be installed will be at the Institut Mutualiste Montsouris in Paris, France.

Endocare cryoablation therapy is a specific form of cryotherapy meant to treat prostate, kidney and lung cancer in a way that is less invasive to the patient. It can also be used in liver metastases and for palliative intervention. Prostate salvage cryotherapy is a treatment that is applied when radiation therapy is unsuccessful and also when evidence suggests that cryotherapy is the better option in patients with prostate cancer that has localized after radiation therapy.

The use of cryotherapy to treat small tumors in the kidney has grown in the last few years because radiologists can use computerized tomography (CT) scanning to increase precision whether the patient is under anesthesia or conscious sedation.